Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Intuitive Surgical, Inc. stock analysis ISRG overview
Bullish +75

INTUITIVE SURGICAL ($ISRG) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative

📈 Intuitive Surgical (ISRG) reported Q1 2026 earnings of $2.50 per share, exceeding analyst estimates of $2.14 by $0.36.

💰 Revenue for the quarter reached $2.77 billion, surpassing the consensus estimate of $2.67 billion by approximately $104 million.

📊 Following the earnings release, the stock price rose 3.76% in after-hours trading on April 21st.

🔍 Insider trading data shows 47 sales and zero purchases of ISRG stock over the past six months.

🏛️ Congressional trading activity included four purchases and no sales of ISRG shares by members of Congress in the last six months.

📉 Institutional investor movement saw 1,235 investors adding shares while 859 decreased their positions in the most recent quarter.

🎖️ Over the last year, the company paid out $1.39 million in awards to its employees and leadership.

💡 Analyst sentiment remains positive with three firms issuing buy ratings and zero firms issuing sell ratings recently.

🎯 A group of 13 analysts have set a median price target of $610 for ISRG stock over the last six months.

📱 The article promotes Quiver Quantitative's various dashboards for tracking insider trading, hedge fund activity, and government contracts.

Bullish Signals
  • INTUITIVE SURGICAL reported Q1 2026 earnings of $2.50 per share, beating Wall Street estimates of $2.14 by $0.36.
  • The company's revenue reached $2.77 billion, surpassing analyst expectations of $2.67 billion.
  • Following the strong earnings release, INTUITIVE SURGICAL stock price gained +3.76% after market close.
  • Wall Street sentiment remains bullish, with 3 firms issuing buy ratings and zero sell ratings in recent months.
  • Analysts maintain a median price target of $610.0 for the stock, indicating continued upside potential.
  • Legislators show confidence in the company, as Members of Congress have purchased $ISRG shares 4 times with no sales over the past 6 months.
Risk Factors
  • Insiders have sold $ISRG stock 47 times in the past six months with zero purchases, indicating significant short-term selling pressure from company insiders.
  • Institutional investors decreased their positions by netting out to a decrease, as 859 investors reduced holdings while only 1,235 added shares during the most recent quarter.
Full Analysis
Intuitive Surgical ($ISRG) released its Q1 2026 quarterly earnings results on Tuesday, April 21st, delivering performance that exceeded analyst expectations for both per-share earnings and revenue. The company reported earnings of $2.50 per share, surpassing the estimated $2.14 by $0.36, while total revenue reached $2,770,800,000, up from the projected $2,667,167,614. This strong financial performance drove the stock price to rise by 3.76% following the market close. The positive reception of the earnings report reflects the company's continued growth in its medical technology sector, validating investor confidence in its operational execution and market position during the first quarter of fiscal year 2026. Corporate governance activity surrounding $ISRG has been mixed among different groups over the past six months, providing a nuanced view of internal sentiment. Insiders have engaged in significant selling activity, trading the stock 47 times with all 47 transactions being sales and zero purchases, indicating a lack of insider buying pressure. Conversely, members of Congress have shown interest by purchasing the stock 4 times with no sales recorded during the same period. Furthermore, institutional ownership has seen net increases as 1,235 institutional investors added shares to their portfolios, although this was partially offset by 859 investors who decreased their positions, with award payments totaling $1,385,220 distributed over the last year. Wall Street analysts maintain a positive outlook on Intuitive Surgical, with recent reports from three firms rating the stock as a buy and zero firms issuing sell ratings. Over the last six months, 13 analysts have provided price targets for the company, establishing a median target of $610.0, which suggests continued interest in long-term potential despite short-term insider selling. The company is also noted for receiving government contracts, though specific details on those were not enumerated in this report. Overall, while there is no direct conflict between the strong earnings beat and insider sales, the combination of robust financials, buy ratings from analysts, and net institutional accumulation points to a stable and bullish market sentiment for $ISRG as of mid-April 2026.